Xcout IntelMariposa Therapeutics
Mariposa Therapeutics Ltd is a biotechnology company founded in 2019 and headquartered in Cardiff, United Kingdom. The company is dedicated to researching and developing innovative therapeutic solutions for keratin-related disorders. Its scientific efforts are supported by specialized research investments aimed at addressing rare skin and tissue conditions.
Subscribe to see Mariposa Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mariposa Therapeutics at a glance
Mariposa Therapeutics is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Seed, raised $995,400 in March 2026. Xcout tracks 7 named people at Mariposa Therapeutics, including Dr David Howat (Chief Executive Officer).
Mariposa Therapeutics leadership
- Dr David HowatChief Executive Officer
- Andres KorinChief Financial Officer
- Dr Lucy SykesChief Scientific Officer
- Carin BeumerChair of the Board
- Thomas HafnerFounder & Executive Director
- Damian MarronNon-Executive Director
1 more named person on record for Mariposa Therapeutics, with roles, board committees and tenure — see the full roster →
Mariposa Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $995,400 | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Mariposa Therapeutics competitors
A few of Mariposa Therapeutics's closest competitors — see the full list of competitors and alternatives →
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Eliksa Therapeutics, Inc. is a venture-backed biotechnology company based in Doylestown, Pennsylvania, specializing in regenerative medicine. The company focuses on developing innovative therapies to treat severe conditions such as Epidermolysis bullosa (EB). Through targeted research and funding, it works to advance clinical solutions for patients with rare genetic skin diseases.
Kamal Therapeutics, Inc. is a pharmaceutical holding company located in Hingham, Massachusetts, focused on developing treatments such as intravenous recombinant human decorin for dystrophic epidermolysis bullosa.
Pathios Therapeutics Limited is a biotech company established in 2017 and registered in England and Wales, focusing on the discovery and development of first-in-class therapies.
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Get Mariposa Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mariposa Therapeutics in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access